Amyloid Cardiomyopathy

Szor, Roberta Shcolnik; Alencar, Aristóteles Comte de; Bueno, Bruno Vaz Kerges; Cafezeiro, Caio Rebouças Fonseca; Alves, Lucas Bassolli de Oliveira; Hajjar, Ludhmila Abrahão; Martínez, Gracia; Rocha, Vanderson; Fernandes, Fábio

doi:10.1016/j.jaccao.2021.06.001

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A formal bias assessment of identified studies is provided in online supplementary Table . The individual studies and the extracted aggregate data are summarized in Table 2 2,3,10,11,13,26,27,29,30,52,54,65,71,78–158 . An exponential growth in the annual publication of studies on clinical outcomes of ATTR was observed over the recent years ( Figure ).…”

Section: Resultsmentioning

confidence: 99%

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis

Antonopoulos

Panagiotopoulos

Kouroutzoglou

et al. 2022

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis

Antonopoulos

Panagiotopoulos

Kouroutzoglou

et al. 2022

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…There remains a significant gap in diagnosis in certain populations, and already published or ongoing randomized trials focused on patients with ATTR-CM, did not include African countries or low-income countries as recruitment centres [299]. However efforts are being made to improve awareness, diagnosis, and management of this condition globally [20,[300][301][302][303]. ATTR-CM poses several challenges in LMICs:…”

Section: Challenges Of Attr-cm In Low and Middle-income Countriesmentioning

confidence: 99%

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Brito,

Albrecht,

de Arenaza

et al. 2023

Global Heart

View full text Add to dashboard Cite

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal condition that requires early diagnosis, management, and specific treatment. The availability of new disease-modifying therapies has made successful treatment a reality. Transthyretin amyloid cardiomyopathy can be either age-related (wild-type form) or caused by mutations in the TTR gene (genetic, hereditary forms). It is a systemic disease, and while the genetic forms may exhibit a variety of symptoms, a predominant cardiac phenotype is often present. This document aims to provide an overview of ATTR-CM amyloidosis focusing on cardiac involvement, which is the most critical factor for prognosis. It will discuss the available tools for early diagnosis and patient management, given that specific treatments are more effective in the early stages of the disease, and will highlight the importance of a multidisciplinary approach and of specialized amyloidosis centres.To accomplish these goals, the World Heart Federation assembled a panel of 18 expert clinicians specialized in TTR amyloidosis from 13 countries, along with a representative from the Amyloidosis Alliance, a patient advocacy group. This document is based on a review of published literature, expert opinions, registries data, patients' perspectives, treatment options, and ongoing developments, as well as the progress made possible via the existence of centres of excellence.From the patients' perspective, increasing disease awareness is crucial to achieving an early and accurate diagnosis. Patients also seek to receive care at specialized amyloidosis centres and be fully informed about their treatment and prognosis.

show abstract

Periorbital Purpura as a Presenting Sign of Hereditary Transthyretin Amyloidosis

2023

View full text Add to dashboard Cite

Amyloid Cardiomyopathy

Cited by 3 publications

References 11 publications

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Periorbital Purpura as a Presenting Sign of Hereditary Transthyretin Amyloidosis

Contact Info

Product

Resources

About